Form D · Biotechnology

Mahzi Therapeutics Inc.

South San Francisco, CA · CIK 0001888808

Offering snapshot reported Jul 8, 2024 · SEC filing

Reported sold
$52.6M
Offering amount: $52.6M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 7, 2021
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$26.3M$52.6MOct 21, 2021: $26,787,382.00Oct 21, 2021Nov 14, 2022: $47,336,425.00Nov 14, 2022Jul 8, 2024: $52,586,424.00Jul 8, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$47,336,425 → $52,586,424
  • Reported investors10 → 11

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 8, 2024Amendment$52,586,424$5,249,999vs Nov 14, 202211SEC filing
Nov 14, 2022Amendment$47,336,425$20,549,043vs Oct 21, 202110SEC filing
Oct 21, 2021Initial$26,787,382No comparison10SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-417994

Source: Form D, filed Jul 8, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Stephen Farr Director
Camille Samuels Director
Shalini Sharp Director
Marten Steen Director
Yael Weiss Director, Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
470 Noor Ave, Ste B, #1036
South San Francisco, CA, 94080